Treatment for chemotherapy-induced peripheral neuropathy using traditional Chinese medicine hot packages

A Randomized Controlled Clinical Stuty on the Treatment and Nursing Care of CIPN Patients With Traditional Chinese Medicine Hot Package

NA · The Fourth Affiliated Hospital of Zhejiang University School of Medicine · NCT06492083

This study is testing if traditional Chinese medicine hot packages can help people with chemotherapy-induced nerve pain feel better while they are undergoing treatment.

Quick facts

PhaseNA
Study typeInterventional
Enrollment90 (estimated)
Ages18 Years and up
SexAll
SponsorThe Fourth Affiliated Hospital of Zhejiang University School of Medicine (other)
Drugs / interventionschemotherapy
Locations1 site (Yiwu, Zhejiang)
Trial IDNCT06492083 on ClinicalTrials.gov

What this trial studies

This clinical trial evaluates the effectiveness of traditional Chinese medicine hot packages in treating chemotherapy-induced peripheral neuropathy (CIPN) in patients undergoing chemotherapy with platinum and taxane drugs. A total of 90 participants will be randomly assigned to either a control group, receiving standard chemotherapy care, or an intervention group, which will also receive hot compress treatments at acupuncture points. The study aims to assess the degree of nerve damage and patient-reported outcomes after chemotherapy cycles. The approach combines modern chemotherapy with traditional Chinese medicine to potentially improve patient quality of life.

Who should consider this trial

Good fit: Ideal candidates are adults undergoing their first chemotherapy regimen with platinum and paclitaxel, expected to survive with their tumor for more than one year.

Not a fit: Patients with allergies to the chemotherapy drugs or Chinese herbal ingredients, as well as those with certain pre-existing conditions like diabetes or severe joint deformities, may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could significantly alleviate symptoms of CIPN, improving the quality of life for patients undergoing chemotherapy.

How similar studies have performed: While traditional Chinese medicine has been used in various contexts, this specific approach to CIPN treatment is novel and has not been extensively tested in prior studies.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Adult and kinetic patients expected survive with tumor for more than 1 year. Those who use platinum in combination with paclitaxel for chemotherapy for the first time; Voluntarily agree to participate and sign a consent form

Exclusion Criteria:

* Those who are allergic to platinum, paclitaxel or Chinese herbal medicine ingredients; Patients with diabetes mellitus, Raynaud's syndrome, central or peripheral nerve disease symptoms; Those who cannot judge their own symptoms; Pregnant / lactating women; Patients with advanced rheumatoid arthritis, severe joint deformity or incapacitation; Those with other immune system diseases; Patients who have not completed the chemotherapy regimen; Patients who were not treated with hot acupuncture points as prescribed (missed dosing ≥ 3 times per week); Incomplete collection of clinical data; Subjects who voluntarily request to withdraw from this treatment, or are unwilling to continue treatment.

Where this trial is running

Yiwu, Zhejiang

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.

View on ClinicalTrials.gov →

Conditions: Chemotherapy, Chemotherapy-Induced Peripheral Neuropathy/CIPN, hot compress with chinese herbal packets

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.